Alyeska Investment Group
SMMT icon

Alyeska Investment Group’s Summit Therapeutics SMMT Stock Holding History

Alyeska Investment Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-49,553
Closed -$639K – 516
2018
Q1 		$639K Sell
49,553
-447
-0.9% -$5.58K 0.01% 411
2017
Q4 		$554K Hold
50,000
– – ﹤0.01% 408
2017
Q3 		$628K Buy
+50,000
New +$648K ﹤0.01% 434

Other funds holding SMMT

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Alyeska Investment Group's SMMT Position: Q2 2018 in Review

Alyeska Investment Group sold out of Summit Therapeutics (SMMT) in Q2 2018, closing a stake of 49,553 shares — an estimated $639K sold.

Alyeska Investment Group first reported a position in SMMT in Q3 2017 and held it in 3 quarters. The position peaked at $639K in Q1 2018. 17 funds tracked by Wall St. Rank hold SMMT as of Q2 2018.

  • Alyeska Investment Group reported no remaining Summit Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 49,553 Summit Therapeutics shares in Q2 2018, an estimated $639K.
  • Alyeska Investment Group first reported a position in Summit Therapeutics in Q3 2017 and held it in 3 quarters.
  • Alyeska Investment Group's Summit Therapeutics position peaked at $639K in Q1 2018.
  • 17 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.